Text Size

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00726323
First received: July 29, 2008
Last updated: May 10, 2012
Last verified: May 2012
History of Changes
  Purpose

This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.


Condition Intervention Phase
Carcinoma, Renal Cell
 Drug: foretinib (formerly GSK1363089 or XL880)
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2 Study of the c-Met RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects With Papillary Renal-Cell Carcinoma

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Best confirmed tumor response rate [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    Primary efficacy


Secondary Outcome Measures:
  • Progression free survival [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    Efficacy secondary endpoint

  • time to response [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    efficacy

  • duration of response [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    efficacy

  • Duration of stable disease [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    efficacy

  • Overall survival [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    efficacy

  • Laboratory tests [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    Safety

  • Adverse events [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    Safety


Enrollment: 74
Study Start Date: June 2006
Estimated Study Completion Date: July 2012
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 5/9 dosing
240 mg of foretinib on a 5 day on / 9 day off regimen every 14 days.
 Drug: foretinib (formerly GSK1363089 or XL880)
treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
Other Name: GSK1363089 (formerly XL880)
Experimental: daily dosing
80 mg foretinib on a daily dosing regimen
 Drug: foretinib (formerly GSK1363089 or XL880)
treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
Other Name: GSK1363089 (formerly XL880)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosis of PRC with metastatic disease or bilateral multifocal renal tumors localized to kidneys. Measurable disease, ECOG performance status of </= 2.
  • Adequate bone marrow reserve, hepatic, renal, and cardiovascular function.

Exclusion Criteria:

  • Radiation to >/=25% of bone marrow within 14 days of GSK1363089, more than 1 prior anti-cancer therapy, received prior treatment with a c-met inhibitor, brain metastases,
  • Any uncontrolled intercurrent illness,
  • Pregnant or breastfeeding,
  • HIV positive
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00726323

Locations
United States, California
GSK Investigational Site
Greenbrae, California, United States, 94904-2007
GSK Investigational Site
San Francisco, California, United States, 94115
GSK Investigational Site
Stanfore, California, United States, 94305
United States, Indiana
GSK Investigational Site
Indianapolis, Indiana, United States, 46202
United States, Maryland
GSK Investigational Site
Bethesda, Maryland, United States, 20892
United States, Massachusetts
GSK Investigational Site
Boston, Massachusetts, United States, 02115
United States, Michigan
GSK Investigational Site
Detroit, Michigan, United States, 48201
United States, New Jersey
GSK Investigational Site
New Brunswick, New Jersey, United States, 08901
United States, Ohio
GSK Investigational Site
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19104
United States, Tennessee
GSK Investigational Site
Nashville, Tennessee, United States, 37232
United States, Texas
GSK Investigational Site
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00726323     History of Changes
Obsolete Identifiers: NCT00345423
Other Study ID Numbers: MET111644
Study First Received: July 29, 2008
Last Updated: May 10, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
c-Met
Papillary Renal Cell Carcinoma(PRC)
Sporadic papillary renal cell carcinoma,
Clear cell renal carcinoma
Hereditary papillary renal cell carcinoma,

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
 Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on May 19, 2013